Emergent BioSolutions Gets Up to $22.3M Pentagon Deal
A contract modification supplies BioThrax vaccine to the Defense Department under an existing option period.
Updated on Nov. 4, 2026 in COVID-19
Emergent BioSolutions received a contract modification valued at up to $22.3 million to supply BioThrax vaccine to the Defense Department. The modification exercises an option period under an existing Pentagon contract and includes an initial delivery valued at about $7.4 million.
Why it matters
The award extends an established supply relationship between the company and the U.S. military for a vaccine used for defense preparedness. It shows how existing government contracts continue to be expanded through option periods rather than new procurement.
The modification has a maximum value of $22.3 million, with an initial delivery of about $7.4 million set for 2026 under the option period. The source does not detail the total number of doses or the precise split of remaining deliveries.
The players
Emergent BioSolutions
Emergent BioSolutions is a biopharmaceutical company that develops and manufactures vaccines and medical countermeasures for government and public health customers.
Defense Department
The Defense Department is the U.S. federal agency responsible for military operations and the procurement of defense-related goods and services.
The details
Emergent BioSolutions received the modification to supply BioThrax, an anthrax vaccine, to the Defense Department. It exercises an option period under the company's existing contract with the Pentagon, with remaining deliveries expected in 2027.
Timeline
2026: Initial delivery of BioThrax valued at about $7.4 million.
2027: Remaining BioThrax deliveries expected.
Big Picture
The award follows the pattern of exercising option periods within existing Pentagon contracts to extend ongoing vaccine supply rather than launching new competitive procurements. It continues a long-standing government reliance on Emergent BioSolutions for anthrax countermeasures.
The contract affects the availability of anthrax vaccine for military personnel and does not change routine access for civilians. Readers should not expect direct changes to public vaccine supply from this award.
The takeaway
Long-running government contracts are often extended through option periods, which can keep essential medical countermeasures in supply without new bidding. Watching these modifications offers a clear view of how federal defense spending sustains specialized vaccine production.
What happens next
Initial delivery of BioThrax valued at about $7.4 million is scheduled for 2026, with remaining deliveries expected in 2027.
Further reading
For more on vaccine policy and public health preparedness, see the COVID-19 coverage section.
Source note: This article includes information reported by Morningstar.
